Burlat, Diobelyn W.
HRN: 04-08-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/27/2022
CEFTRIAXONE 1G (VIAL)
04/27/2022
05/03/2022
IV
2grams
Q24hrs
Breast CA
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes